Page 65 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat
P. 65

Table  1: Comparison of clinical characteristics  between  HCC patients  with BCLC

                   stage B and those with BCLC stage C



                                             Total                      BCLC classification
                                                                                                      P value
                                             (n=22)             B (n=8)           C (n=14)

           Age, years                        67 (39-89)         65 (58-89)        68 (39-86)         0.973
           Male, n (%)                       20 (90.9)          8 (100%)          12 (85.7)          0.166

           Etiology of hepatitis, n (%)                                                              0.842

              HBV                            11 (50)            4 (50.0)          7 (50.0)
              HCV                            6 (27.3)           3 (37.5)          3 (21.4)
              Alcohol                        2 (9.1)            0                 2 (14.3)

              Unknown                        3 (13.6)           1 (12.5)          2 (14.3)

           Cirrhosis, n (%)                  22 (100)           8 (100)           14 (100)           NA
           Child-Pugh class, n (%)                                                                   0.593

              A                              18 (81.8)          7 (87.5)          11 (78.6)
              B                              4 (18.2)           1 (12.5)          3 (21.4)

           ALBI grade                                                                                0.117
              1                              3 (13.6)           2 (25.0)          1 (7.1)

              2                              18 (81.8)          5 (62.5)          13 (92.9)
              3                              1 (4.5)            1 (12.5)          0

           Baseline AFP, ng/ml               191.8              19.2              356.56             0.212
                                             (1.7-30748.9)      (4.2-30748.9)     (1.7-5503.4)

           Previous Nexavar, n (%)           20 (90.9)          7 (87.5)          13 (92.9)          0.679
           Nivolumab dosage, n (%)                                                                   0.243

              ≤1 mg/kg                       9 (40.9)           2 (25.0)          7 (50.0)
              >1mg/kg                        13 (59.1)          6 (75.0)          7 (50.0)

           Mean OS, month                    18.1±2.6           20.5±3.0          14.2±1.7           0.334
           Median PFS, month                 8.1 (0.9-25.2)     8.2 (1.77-25.2)   7.6 (1.25-19.61)   0.367

           Response rate, %
              CR                             13.6               12.5              14.3               0.906

              PR                             27.3               25.0              28.6               0.856
              SD                             31.8               50.2              21.4               0.170

              PD                             27.3               12.5              35.7               0.220
           DCR, %                            72.7               87.5              64.3               0.220
   60   61   62   63   64   65   66   67   68   69   70